Laboratory of Molecular Pharmacology, GIGA-Molecular Biology of Diseases, ULiège, Belgium.
Laboratory of Molecular Pharmacology, GIGA-Molecular Biology of Diseases, ULiège, Belgium; Laboratory of Medicinal Chemistry, CIRM-Drug target and Lead Discovery, ULiège, Belgium.
Biochem Pharmacol. 2018 Jul;153:62-74. doi: 10.1016/j.bcp.2018.02.016. Epub 2018 Feb 15.
G protein-coupled receptors (GPCRs) are usually highlighted as being both the largest family of membrane proteins and the most productive source of drug targets. However, most of the GPCRs are understudied and hence cannot be used immediately for innovative therapeutic strategies. Besides, there are still around 100 orphan receptors, with no described endogenous ligand and no clearly defined function. The race to discover new ligands for these elusive receptors seems to be less intense than before. Here, we present an update of the various strategies employed to assign a function to these receptors and to discover new ligands. We focus on the recent advances in the identification of endogenous ligands with a detailed description of newly deorphanized receptors. Replication being a key parameter in these endeavors, we also discuss the latest controversies about problematic ligand-receptor pairings. In this context, we propose several recommendations in order to strengthen the reporting of new ligand-receptor pairs.
G 蛋白偶联受体 (GPCRs) 通常被认为是最大的膜蛋白家族,也是最有成效的药物靶点来源。然而,大多数 GPCR 研究不足,因此不能立即用于创新的治疗策略。此外,还有大约 100 种孤儿受体,没有描述的内源性配体,也没有明确的功能。寻找这些难以捉摸的受体的新配体的竞赛似乎不如以前激烈了。在这里,我们介绍了用于为这些受体赋予功能和发现新配体的各种策略的最新进展。我们重点介绍了最近在鉴定内源性配体方面的最新进展,并详细描述了新的去孤儿化受体。复制是这些努力中的关键参数,我们还讨论了关于有问题的配体-受体配对的最新争议。在这种情况下,我们提出了一些建议,以加强新的配体-受体对的报告。